Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias

ConditionVentricular Arrythmia

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-80

SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

The investigation of biomarkers for immune status and metabolic state, as well as host microbiota composition, in patients with ventricular arrhythmias before and after radiofrequency ablation, can provide new insights for specific and personalized treatment. This can help establish early prediction and prognosis models and provide a basis for clinically effective diagnosis and treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.

Disqualifiers

Age <18 or >80 years old;

Patients with autoimmune diseases or immune deficiencies, or those who have used immunosuppressive or immune modulating agents in the past 3 months;

Platelet count <100×10^9/L or functional platelet defects;

Congenital or acquired coagulation or bleeding disorders;

Trial population

Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Observational; No Interventions were given.
Other intervention
Observational; No Interventions were given.

Treatment groups

5,000 Participants

are divided into 5 treatment groups

Group A: Occasional premature ventricular contractions group1 intervention

Group B: Frequent premature ventricular contractions group1 intervention

Group C: Short runs of ventricular tachycardia group1 intervention

Group D: Sustained ventricular tachycardia group1 intervention

Group E: Ventricular fibrillation group1 intervention

Trial outcomes

Primary outcomes

Change in the incidence of MACCE

Major adverse cardiovascular and cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.

Time frame